Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 85.91% is in line with its 5-year average of 86.46%, around the middle of its 5-year range (79.57%–90.59%).
0.39% below its 12-month average of 86.25%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 88.82%.
GROSS MARGIN
85.91%
GROSS MARGIN AVG TTM
86.25%
GROSS MARGIN AVG 3Y
87.91%
GROSS MARGIN AVG 5Y
86.46%
GROSS MARGIN AVG 10Y
81.34%
GROSS MARGIN AVG 15Y
78.75%
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-0.39%
CURRENT VS 3Y AVG
-2.27%
CURRENT VS 5Y AVG
-0.64%
CURRENT VS 10Y AVG
+5.62%
CURRENT VS 15Y AVG
+9.09%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
39.32%
median of 679 covered companies
CURRENT VS SECTOR MEDIAN
+118.49%
vs the sector median at left
Market Cap
$147.54M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$146.58M
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
-394.61%
5Y Avg
-639.25%
Market Cap
$146.29M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
12.53%
5Y Avg
23.21%
Market Cap
$150.59M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-76.15%
Market Cap
$152.45M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$153.31M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-29.98%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| LifeMD, Inc. (LFMDP) | $147.97M | 85.91% | 86.25% | 87.91% | 86.46% |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $147.54M | 0.00% | 0.00% | 0.00% | 0.00% |
| Korsana Biosciences, Inc. (KRSA)vs › | $146.58M | 100.00% | 100.00% | -394.61% | -639.25% |
| Immuneering Corporation (IMRX)vs › | $146.29M | 0.00% | 0.00% | 12.53% | 23.21% |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $150.59M | 0.00% | 0.00% | 0.00% | -76.15% |
| Anavex Life Sciences Corp. (AVXL)vs › | $152.45M | 0.00% | 0.00% | 0.00% | 0.00% |
| Codexis, Inc. (CDXS)vs › | $152.74M | 83.71% | 79.64% | 78.40% | 78.75% |
| Nyxoah S.A. (NYXH)vs › | $143.10M | 63.13% | 64.40% | 63.36% | 62.40% |
| Cardiol Therapeutics Inc. (CRDL)vs › | $153.31M | 0.00% | 0.00% | 0.00% | -29.98% |
| AirSculpt Technologies, Inc. (AIRS)vs › | $142.15M | 57.63% | 59.89% | 61.87% | 62.78% |
Gross Margin
85.9%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 88.82% |
| 2026-03-31 | 84.85% |
| 2025-12-31 | 81.82% |
| 2025-09-30 | 87.69% |
| 2025-06-30 | 88.06% |
| 2025-03-31 | 86.84% |
| 2024-12-31 | 85.32% |
| 2024-09-30 | 90.59% |
| 2024-06-30 | 90.08% |
| 2024-03-31 | 89.58% |
| 2023-12-31 | 88.06% |
| 2023-09-30 | 87.62% |
| 2023-06-30 | 87.35% |
| 2023-03-31 | 87.28% |
| 2022-12-31 | 85.53% |
| 2022-09-30 | 84.98% |
| 2022-06-30 | 84.78% |
| 2022-03-31 | 81.93% |
| 2021-12-31 | 79.69% |
| 2021-09-30 | 79.57% |
| 2021-06-30 | 81.53% |
| 2021-03-31 | 82.07% |
| 2020-12-31 | 69.09% |
| 2020-09-30 | 84.78% |
| 2020-06-30 | 75.90% |
| 2020-03-31 | 59.12% |
| 2019-12-31 | 87.02% |
| 2019-09-30 | 78.25% |
| 2019-06-30 | 75.72% |
| 2019-03-31 | 74.88% |
| 2018-12-31 | 70.74% |
| 2018-09-30 | 82.38% |
| 2018-06-30 | 73.76% |
| 2018-03-31 | 77.87% |
| 2017-12-31 | 71.75% |
| 2017-09-30 | 73.90% |
| 2017-06-30 | 70.27% |
| 2017-03-31 | 52.09% |
| 2016-12-31 | 31.26% |
| 2016-09-30 | 31.90% |
| 2016-06-30 | 42.88% |
| 2016-03-31 | 18.47% |
| 2015-12-31 | 97.30% |
| 2015-09-30 | 73.56% |
| 2015-06-30 | 67.73% |
| 2015-03-31 | 74.26% |
| 2014-12-31 | 89.35% |
| 2014-09-30 | 56.73% |
| 2014-06-30 | 64.83% |
| 2014-03-31 | 74.49% |
| 2013-12-31 | 64.42% |
| 2013-09-30 | 81.54% |
| 2013-06-30 | 79.66% |
| 2013-03-31 | 85.96% |
| 2012-12-31 | 156.39% |
| 2012-09-30 | 64.60% |
| 2012-06-30 | 54.39% |
| 2012-03-31 | 83.44% |
